BC is a heterogeneous disease where patient classification and treatment decisions are primarily based on the immunohistochemistry assays that assess expression of estrogen (ER) and progesterone (PR) hormone receptors, as well as of HER2 tyrosine kinase receptor. Here, NR4A1 is linked to breast cancer.